Breckenridge Announces Approval of Anastrozole Tablets
Product to be launched June 2010. - June 28, 2010

Breckenridge Announces Approval of Terbinafine HCl Tablets
Product to be launched during summer of 2010. - June 4, 2010

Breckenridge Signs with Genepharm Trading
Will commercialize two ANDAS - November 10, 2009

Breckenridge Announces Approval of Cilostazol Tablets®
Product launch plans currently being finalized. - September 28, 2009

Breckenridge Signs with Orit
Will market Ergocalciferol (Vitamin D) Capsules. - August 17, 2009

Breckenridge Enters Agreement with Helm
Will develop third ANDA project. - Dec. 23, 2008

Breckenridge Announces Approval of Generic
Will market Novo Nordisk's generic Activella®. - April 17, 2008

Breckenridge Enters Agreement With Helm AG
Will develop and manufacture a generic ANDA product. - March 31, 2008

Breckenridge Settles "Paragraph IV" Litigation
FDA Approves Oxcarbazepine; generic version of Trileptal(R). - January 11, 2008

Breckenridge Signs Long Term Agreement with Helm AG (Hamburg, Germany)
Will develop and market generic tablet and ANDA product – December 18, 2007

Breckenridge Enters Agreement with Chemo/Liconsa
Companies to manufacture and market Generic ANDA – june 25, 2007

Breckenridge Announces New VP
Anthony R. Mihelich, R.Ph named new VP of Corporate Development, Feb. 5, 2007

Breckenridge Files ANDA for Oxcarbazepine
Seizure drug to be added to Breckenridge inventory, Sept. 15, 2006

Breckenridge Enters Marketing Agreement
Will market PEG3350, generic version of Miralax®, Sept. 29, 2006

Breckenridge to Market Meloxicam
FDA approval received to market 7.5mg and 15mg tablets, July 19, 2006

Florida Pedigree Compliance
Effective July 1, 2006